Viatris Inc. (VTRS)
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Profile
Viatris Inc.
- Exchange
- NASDAQ
- Ticker
- VTRS
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- US
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Key facts
Viatris Inc.: key facts
- Viatris Inc. (NASDAQ: VTRS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector.
- In fiscal 2025, Viatris Inc. reported revenue of $14.3B and net income of -$3.5B.
- Revenue fell 5.4% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 2 of the last 5 fiscal years.
- Over the last twelve months, revenue was $14.7B and net income was -$410.7M.
MonkScore
Viatris Inc.'s MonkScore
MonkScore
MonkScore range: 50–60
as of October 2026
Sector rank: 323 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth50–60
- Profitability20–30
- Quality70–80
- Market Conviction30–40
- Safety70–80
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Viatris Inc.'s annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $14.7B | $14.3B | $14.7B | $15.4B | $16.3B | $17.9B |
| Gross profit | $5.1B | $5.0B | $5.6B | $6.4B | $6.5B | $5.6B |
| Operating income | -$87.3M | -$2.7B | $10.1M | $766.2M | $1.6B | -$34.0M |
| Net income | -$410.7M | -$3.5B | -$634.2M | $54.7M | $2.1B | -$1.3B |
| Operating cash flow | $2.3B | $2.3B | $2.3B | $2.8B | $3.0B | $3.0B |
| Capital expenditure | -$457.7M | -$378.8M | -$326.0M | -$474.5M | -$489.4M | -$509.4M |
| Free cash flow | $1.9B | $1.9B | $2.0B | $2.3B | $2.5B | $2.5B |
| Total debt | $13.6B | $14.7B | $14.3B | $18.4B | $19.5B | $23.4B |
| Cash | $886.5M | $1.3B | $734.8M | $991.9M | $1.3B | $701.2M |
Revenue growth a year
- 1-year
- -3.0%
- 3-year
- -4.2%
- 4-year
- -5.4%
Compound growth between fiscal years.
Peers
Similar companies
- Amphastar Pharmaceuticals, Inc.NASDAQ:AMPHMonkScore range: 50–60
- Phibro Animal Health CorporationNASDAQ:PAHCMonkScore range: 50–60
- Pacira BioSciences, Inc.NASDAQ:PCRXMonkScore range: 60–70
- Alpha Teknova, Inc.NASDAQ:TKNOMonkScore range: 60–70
- Trulieve Cannabis Corp.NYSE:TRLVMonkScore range: 60–70
- Collegium Pharmaceutical, Inc.NASDAQ:COLLMonkScore range: 60–70
- Alkermes plcNASDAQ:ALKSMonkScore range: 70–80
- Harrow Health, Inc.NASDAQ:HROWMonkScore range: 70–80
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.